Alkermes (NASDAQ:ALKS) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$378.1m (flat on 3Q 2023).
- Net income: US$92.8m (up 94% from 3Q 2023).
- Profit margin: 25% (up from 13% in 3Q 2023).
- EPS: US$0.57 (up from US$0.29 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alkermes EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%.
Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 24% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 5.2% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Alkermes you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:ALKS
Alkermes
A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Flawless balance sheet and undervalued.
